These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 31662200

  • 1. The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy.
    Nakajo M, Kitajima K, Kaida H, Morita T, Minamimoto R, Ishibashi M, Yoshiura T.
    Clin Radiol; 2020 Jan; 75(1):79.e9-79.e18. PubMed ID: 31662200
    [Abstract] [Full Text] [Related]

  • 2. Assessment of tumor response to definitive chemoradiotherapy and prognosis prediction in patients with esophageal cancer judged by PET response criteria in solid tumors: multicenter study in Japan.
    Kitajima K, Kaida H, Nakatani K, Ishibashi M, Morita T, Nakajo M, Tamaki Y, Minamimoto R.
    Nucl Med Commun; 2020 May; 41(5):443-451. PubMed ID: 32187159
    [Abstract] [Full Text] [Related]

  • 3. Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST.
    Katsuura T, Kitajima K, Fujiwara M, Terada T, Uwa N, Noguchi K, Doi H, Tamaki Y, Yoshida R, Tsuchitani T, Fujita M, Yamakado K.
    Ann Nucl Med; 2018 Aug; 32(7):453-462. PubMed ID: 29858797
    [Abstract] [Full Text] [Related]

  • 4. Texture analysis of 18F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy.
    Nakajo M, Jinguji M, Nakabeppu Y, Nakajo M, Higashi R, Fukukura Y, Sasaki K, Uchikado Y, Natsugoe S, Yoshiura T.
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
    [Abstract] [Full Text] [Related]

  • 5. The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.
    Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML.
    Radiat Oncol; 2017 Jan 05; 12(1):4. PubMed ID: 28057034
    [Abstract] [Full Text] [Related]

  • 6. The utility of 68F-FDG PET/CT for evaluation of tumor response to immune checkpoint inhibitor therapy and prognosis prediction in patients with non-small-cell lung cancer.
    Kitajima K, Kawanaka Y, Komoto H, Minami T, Yokoi T, Kuribayashi K, Kijima T, Nakamura A, Hashimoto M, Kondo N, Hasegawa S, Yamakado K.
    Hell J Nucl Med; 2021 Jan 05; 24(3):186-198. PubMed ID: 34901959
    [Abstract] [Full Text] [Related]

  • 7. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
    Moore JL, Subesinghe M, Santaolalla A, Green M, Deere H, Van Hemelrijck M, Lagergren J, Chicklore S, Maisey N, Gossage JA, Kelly M, Baker CR, Davies AR, Guy’s and St Thomas’ Oesophago-gastric Research Group.
    Eur Radiol; 2023 May 05; 33(5):3647-3659. PubMed ID: 36920518
    [Abstract] [Full Text] [Related]

  • 8. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J.
    J Med Imaging Radiat Oncol; 2016 Apr 05; 60(2):231-8. PubMed ID: 26678718
    [Abstract] [Full Text] [Related]

  • 9. Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan.
    Kitajima K, Nakatani K, Yamaguchi K, Nakajo M, Tani A, Ishibashi M, Hosoya K, Morita T, Kinoshita T, Kaida H, Miyoshi Y.
    Eur J Nucl Med Mol Imaging; 2018 Sep 05; 45(10):1661-1671. PubMed ID: 29754160
    [Abstract] [Full Text] [Related]

  • 10. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K, Nielsen D, Jensen BV, Hendel HW.
    J Nucl Med; 2013 Jul 05; 54(7):1026-31. PubMed ID: 23572497
    [Abstract] [Full Text] [Related]

  • 11. Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan.
    Kaida H, Kitajima K, Nakajo M, Ishibashi M, Matsunaga T, Minamimoto R, Hirata K, Nakatani K, Hung A, Hattori S, Yasuda T, Ishii K.
    Eur J Nucl Med Mol Imaging; 2021 Oct 05; 48(11):3666-3682. PubMed ID: 33934168
    [Abstract] [Full Text] [Related]

  • 12. Pretreatment CT and 18 F-FDG PET-based radiomic model predicting pathological complete response and loco-regional control following neoadjuvant chemoradiation in oesophageal cancer.
    Rishi A, Zhang GG, Yuan Z, Sim AJ, Song EY, Moros EG, Tomaszewski MR, Latifi K, Pimiento JM, Fontaine JP, Mehta R, Harrison LB, Hoffe SE, Frakes JM.
    J Med Imaging Radiat Oncol; 2021 Feb 05; 65(1):102-111. PubMed ID: 33258556
    [Abstract] [Full Text] [Related]

  • 13. 3'-Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies.
    Kim JE, Chae SY, Kim JH, Kim HJ, Kim TW, Kim KP, Kim SY, Lee JL, Oh SJ, Kim JS, Ryu JS, Moon DH, Hong YS.
    Eur J Nucl Med Mol Imaging; 2019 Jul 05; 46(8):1713-1722. PubMed ID: 31041456
    [Abstract] [Full Text] [Related]

  • 14. Prediction of disease-free survival using relative change in FDG-uptake early during neoadjuvant chemoradiotherapy for potentially curable esophageal cancer: A prospective cohort study.
    Hagen PV, Heijl MV, van Berge Henegouwen MI, Boellaard R, Bossuyt PM, Kate FJ, Dekken HV, Hoekstra OS, Sloof GW, Lanschot JJ.
    Dis Esophagus; 2017 Feb 01; 30(2):1-7. PubMed ID: 27001344
    [Abstract] [Full Text] [Related]

  • 15. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
    Depardon E, Kanoun S, Humbert O, Bertaut A, Riedinger JM, Tal I, Vrigneaud JM, Lasserre M, Toubeau M, Berriolo-Riedinger A, Dygai-Cochet I, Fumoleau P, Brunotte F, Cochet A.
    PLoS One; 2018 Feb 01; 13(7):e0199529. PubMed ID: 30011328
    [Abstract] [Full Text] [Related]

  • 16. The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer.
    Guo R, Yan W, Wang F, Su H, Meng X, Xie Q, Zhao W, Yang Z, Li N.
    Cancer Imaging; 2024 Sep 10; 24(1):120. PubMed ID: 39256860
    [Abstract] [Full Text] [Related]

  • 17. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK, Chang YC, Tseng CK, Hsieh CH, Chao YK, Su PJ, Hou MM, Yang CK, Pai PC, Lin CR, Hsieh CE, Wu YY, Hung TM.
    Dis Esophagus; 2017 Aug 01; 30(8):1-10. PubMed ID: 28575243
    [Abstract] [Full Text] [Related]

  • 18. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
    Nakajo M, Kitajima K, Toriihara A, Arigami T, Daisaki H, Nakamura A, Ohtsuka T, Miwa H, Yoshiura T.
    Medicine (Baltimore); 2021 Apr 16; 100(15):e25494. PubMed ID: 33847661
    [Abstract] [Full Text] [Related]

  • 19. The early prediction of pathological response to neoadjuvant chemotherapy and prognosis: comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer criteria in breast cancer.
    Lian W, Liu C, Gu B, Zhang J, Lu L, Pan H, Yao Z, Wang M, Song S, Zhang Y, Yang Z.
    Nucl Med Commun; 2020 Mar 16; 41(3):280-287. PubMed ID: 32032193
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.